Coronary atherosclerotic heart disease (Coronary atherosclerotic heart disease) is the cause of atherosclerosis organ of the most common type of lesion, but also seriously endangers the health of the people of the common diseases, and angina pectoris is a common type of coronary heart disease. In recent years the incidence of coronary heart disease in our country showed an upward trend year after year, and the trend of younger age. In general, the majority of patients with angina pectoris survive for many years, but has happened the risk of AMI or SD, clinical research has become the hot spot. At present, the treatment of this disease is divided into drug treatment, interventional therapy and surgery. Drug treatment such as expansion of coronary artery, anticoagulant, inhibiting platelet aggregation, stable atherosclerotic plaques and so on, although the effect of the ideal, because of the toxic side effects, contraindications, and thus limiting the clinical application of these drugs. Interventional treatment from the initial angioplasty to stenting following, has been more than 30 years, and has rapid development. It could cure patients with symptoms and improve the prognosis of patients apparently, has become an important mode of treatment of coronary heart disease, but treatment has its indications, and high technical requirements, high cost, there are still some difficult problems, such as the long-term patency rate after stenting, the high-risk of unprotected left main disease in PCI and so on. Surgical treatment is the implementation of aortic-coronary artery bypass graft surgery under cardiopulmonary bypass, it has the disadvantages such as major trauma, slow rehabilitation and so on, surgery itself can be complicated by myocardial infarction, and has surgical mortality less than 5%, the blood vessels after transplantation also can be occluded. Therefore, studying the pathogenesis of coronary heart disease, developing effective drug from traditional Chinese medicine for the disease, especially with advanced technology, quick absorption, the role of a more complete form of pills, have broad prospects for development. I conducted a clinical research of Fengjiaozonghuangtong Diwan.Objective: Made a preliminary evaluation on the clinical safety and efficacy of Fengjiaozonghuangtong Diwan treat coronary artery disease angina. Explore the doses of clinical use of Fengjiaozonghuangtong Diwan.Method: Divide eligible patients with coronary artery disease angina 96 cases into test group and control group by taking a random, double-blind, control method. The test group 1 applies Fengjiaozonghuangtong Diwan   Fengjiaozonghuangtong Diwan analog agents, the test group 2 applies Fengjiaozonghuangtong Diwan, and the control group applies Fengjiaozong huangtong Diwan analog agents. During the test prohibit using other Chinese and Western drugs which could treat coronary heart disease except nitroglycerin. The treatment time is 28 days. Observe the effect of angina pectoris, the electrocardiogram, and the Chinese medicine symptom and the security of this drug after the treatment.Result: The results of this study show that the effect of angina pectoris, the electrocardiogram, and the Chinese medicine symptom of the test group 1 and test group 2 are better than the control group. Both have a statistically significant difference(P0.05). On the aspect of angina pectoris, the total effective rate of test group 1 is 65.625%, test group 2 is 71.875%, and the control group is 12.5%; on the aspect of ECG, the total effective rate of test group 1 is 40.625%, test group 2 is 40.625%, and the control group is 9.375%; on the aspect of the Chinese medicine symptom, the total effective rate of test group 1 is 71.875%, test group 2 is 81.25%, and the control group is 34.375%.During the whole course of this clinical research, serious adverse events and test drug-related adverse reactions had never happened.Conclusion: 1.Fengjiaozonghuangtong Diwan is safe and effective treatment of angina pectoris. 2.For the treatment of angina pectoris, there is no significant difference between oral Fengjiaozonghuangtong Diwan 20 capsules each time and oral 30 capsules each time, but not, except that the small number of samples has bearing on this result.